Hepatische Enzephalopathie - Therapie

Die primären therapeutischen Maßnahmen bei hepatischer Enzephalopathie bestehen in der Erkennung und Beseitigung auslösender Faktoren. Die weitere Therapie zielt in erster Linie auf eine Verringerung der Bildung und Resorption toxischer Metabolite im Darm mittels Eiweißrestriktion, Laktulose und oraler Antibiotika. L-Ornithin-L-Aspartat verbessert die Ammoniakentgiftung und die klinische Symptomatik. Bei hepatischer Enzephalopathie im Rahmen eines akuten Leberversagens können hirndrucksenkende Maßnahmen erforderlich sein.

Literatur

• 1 Conn H O, Leevy C M, Vlahcevic Z R, Rodgers J B. et al . Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double-blind controlled trial.  Gastroenterology. 1977;  72 573-578
• 2 Häussinger D, Steeb R, Gerok W. Metabolic alkalosis as driving force for urea synthesis in liver disease: pathogenic model and therapeutic implications.  Clin Invest. 1992;  70 411-415
• 3 Heemann U, Treichel U, Loock J, Philipp T. et al . Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.  Hepatology. 2002;  36 949-958
• 4 Horst D, Grace N D, Conn H O, Schiff E. et al . Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial.  Hepatology. 1984;  4 279-287
• 5 Huber M, Rössle M, Siegerstetter V, Ochs A. et al . Helicobacter pylori infection does not correlate with plasma ammonia concentration and hepatic encephalopathy in patients with cirrhosis.  Hepatogastroenterology. 2001;  48 541-544
• 6 Kircheis G, Nilius R, Berndt H, Buchner M. et al . Therapeutic efficacy of L-ornithine-L-aspartate infusion concentrate in patients with liver cirrhosis and hepatic encephalopathy: A placebo-controlled double-blind study.  Hepatology. 1997;  25 1351-1360
• 7 Kircheis G, Wettstein M, vom Dahl S, Häussinger D. Clinical efficacy of L-ornithine-L-asparate in the management of hepatic encephalopathy.  Metabolic Brain Disease. 2002;  17 453-462
• 8 Laccetti M, Manes G, Uomo G, Lionello M. et al . Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study.  Dig Liv Dis. 2000;  32 335-338
• 9 Marchesini G, Dioguardi F S, Bianchi G P. et al . Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy.  A randomized double-blind casein-controlled trial J Hepatol. 1990;  11 1-10
• 10 Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis.  Hepatology. 1996;  23 1084-1092
• 11 Mas A, Rodés J, Sunyer L, Rodrigo L. et al . Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled trial.  J Hepatol. 2003;  38 51-58
• 12 Morgan M Y, Hawley K E. A randomized double-blind trial of lactitol and lactulose in acute hepatic encephalopathy in cirrhotic patients.  Hepatology. 1987;  7 1278-1284
• 13 Naylor C D, O’Rourke K, Detoky A J, Baker J P. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy: A meta-analysis.  Gastroenterology. 1989;  97 1033-1042
• 14 Stauch S, Kircheis G, Adler G, Beckh K. et al . L-ornithine-L-aspartate granulate in the treatment of latent and mild chronic hepatic encephalopathy (HE): A placebo-controlled double-blind study.  Journal of Hepatology. 1998;  28 856-864
• 15 Uribe M, Campollo O, Vargas F, Ravelli G P. et al . Acidifying enemas (lactitol and lactose) versus nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial.  Hepatology. 1987;  7 639-643
• 16 Tromm A, Griga T, Greving I, Hilden H. et al . Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.  Hepatogastroenterology. 2000;  47 473-477
• 17 Schepke M, Reichel C, Ziske C, Spengler U, Caselmann W H, Sauerbruch T. Leberzirrhose - Komplikationen und Therapie.  Dtsch Med Wochenschr. 2001;  36 975-984